composite implant, termed the California Project to Cure Blindness-Retinal
Pigment Epithelium 1 (CPCB-RPE1), which consists of a polarized monolayer of
human embryonic stem cell-derived RPE (hESC-RPE) on an ultrathin parylene
substrate, may improve visual function in some patients with non-neovascular age-related
macular degeneration (NNAMD), a study published online in Science
Translational Medicine has revealed.
Kashani, M.D., Ph.D., from the University of Southern California in Los
Angeles, and colleagues conducted an interventional U.S. Food and Drug
Administration-cleared phase 1/2a study to assess the safety and efficacy of a
in patients with advanced NNAMD.
interim analysis of the phase 1 cohort comprising five subjects, four of the
subjects successfully received the composite implant. The researchers
identified changes consistent with hESC-RPE in all implanted subjects on
optical coherence tomography imaging, as well as host photoreceptor
integration. There was no progression to vision loss in any of the implanted
eyes; one eye improved by 17 letters, and two demonstrated improved fixation.
concurrent structural and functional findings suggest that CPCB-RPE1 may
improve visual function, at least in the short term, in some patients with
severe vision loss from advanced NNAMD,” the authors wrote.
Kashani et al: A bioengineered retinal pigment epithelial monolayer for
advanced, dry age-related macular degeneration; http://stm.sciencemag.org/content/10/435/eaao4097